Establishment Labs Holdings (NASDAQ: ESTA) appointed Raj Denhoy as head of strategy and investor relations to help define and execute the company’s corporate strategy and communicate that vision to investors and other...
Profound Medical (NASDAQ:PROF; TSX:PRN) appointed seasoned healthcare investment professional Cynthia Lavoie, Ph.D., to the board of the commercial-stage medical device company that develops and markets customizable...
Nurx, a telehealth platform providing convenient and affordable care for female health needs, appointed Dr. Jennifer Peña, M.D., as chief medical officer to help Nurx build on a record year of growth and begin treating...
Glenn Noronha, PhD, has joined PYC Therapeutics (ASX:PYC) as chief development officer to oversee the company’s translational clinical development, regulatory, manufacturing and preclinical development activities as it...
iBio (NYSE American:iBio) appointed Robert Lutz as chief financial and business officer (CFBO), effective March 4, 2021. Mr. Lutz will lead iBio’s finance organization and be responsible for building strong licensing...
Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Todd Hobbs, M.D., to the newly created position of chief medical officer, effective Feb. 16, 2021. In this role, Dr. Hobbs will help lead Hepion as it engages with the FDA...
Closely-held PharmaJet appointed Marian Wentworth, president and CEO of Management Sciences for Health since 2017, to its board. Management Sciences for Health is a non-profit organization that works with low- and...
Jim Lilly joined England & Co., a middle-market investment bank, as a managing director in its New York office. Mr. Lilly brings more than 30 years of experience as a strategic advisor to a wide variety of...
BTIG has expanded its healthcare research coverage, adding Justin Zelin to its research and strategy division as a director. His biotech research coverage will include cell therapy, targeted oncology, immunology and...
IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) appointed Tommy Kenny as VP intellectual property and legal affairs, general counsel of IntelGenx Corp., the company’s operating subsidiary. Mr. Kenny has been with...
Closely-held Fibrocor Therapeutics appointed Joseph Walewicz, a biotech veteran with more than 25 years of experience in finance, capital markets and business development, as CFO. Prior to joining Fibrocor, Mr. Walewicz...
iBio (NYSE American:IBIO) appointed Martin Brenner, Doctor of Veterinary Medicine, Ph.D., as chief scientific officer, effective Jan. 18, 2021. Dr. Brenner has a strong history of success heading drug discovery and...
PDS Biotechnology (NASDAQ:PDSB) appointed Seth Van Voorhees, Ph.D., as its new CFO, effective Jan. 1, 2021. He replaces Michael King, who served as interim CFO. Dr. Van Voorhees most recently was CFO of Research...
Benjamin Bowen, Ph.D., has joined Roth Capital Partners as managing director, healthcare investment banking. Prior to joining Roth, Dr. Bowen most recently was managing director in the investment banking group at...
Profound Medical (NASDAQ:PROF; TSX:PRN) appointed financial executive, Murielle Lortie, as a director, effective immediately. Ms. Lortie is the CFO of Liminal Biosciences, a Nasdaq-listed, clinical-stage...
ObsEva (NASDAQ:OBSV) appointed Brian O’Callaghan as CEO, effective Dec. 1. He succeeds ObsEva’s co-founder, Ernest Loumaye, M.D., Ph.D., who is retiring from his role as CEO but will remain a director of the company. Mr...
Marizyme (NASDAQ:MRZM) appointed Neil Campbell, Ph.D., as CEO, replacing executive chairman James Sapirstein, who has been the company’s interim CEO since September 2020. Dr. Campbell currently serves as chairman of...
LogicBio Therapeutics (NASDAQ:LOGC) appointed Mariana Nacht, Ph.D., as CSO, effective Nov. 30; and promoted Kyle Chiang, Ph.D., to the role of COO, effective Nov. 2. The company is expanding its leadership team to...
Aethlon Medical (NASDAQ:AEMD) appointed Charles Fisher, M.D., as CEO, effective Oct. 30. Dr. Fisher joined Aethlon as a member of its board and served as its chairman since November 2017. He succeeds Dr. Timothy Rodell...
iBio (NYSE AMERICAN:IBIO) appointed biotech industry veteran, Randy Maddux, as COO, effective Dec. 1. Mr. Maddux has more than 20 years of global biologics drug development and manufacturing, business development and...
Soliton (NASDAQ:SOLY) named Brad Hauser as president and CEO as the company prepares for its commercial launch. Mr. Hauser most recently was VP of R&D and general manager for CoolSculpting at Allergan Aesthetics, an...
Closely-held Fibrocor Therapeutics appointed industry veteran, William Fanslow Ph.D., as SVP of drug development. Dr. Fanslow has more than 20 years of experience in drug development, including both small molecules and...
Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.